US20100074949A1
(en)
|
2008-08-13 |
2010-03-25 |
William Rowe |
Pharmaceutical composition and administration thereof
|
US6858615B2
(en)
|
2002-02-19 |
2005-02-22 |
Parion Sciences, Inc. |
Phenyl guanidine sodium channel blockers
|
CA2537841A1
(en)
|
2003-09-06 |
2005-03-24 |
Vertex Pharmaceuticals Incorporated |
Modulators of atp-binding cassette transporters
|
DE602004022319D1
(de)
*
|
2003-11-14 |
2009-09-10 |
Vertex Pharma |
Thiazole udn oxazole als modulatoren von atp-bindungs-kassetten-transportern
|
US7977322B2
(en)
|
2004-08-20 |
2011-07-12 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-binding cassette transporters
|
EP2530075A3
(en)
|
2004-06-24 |
2014-12-24 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-binding cassette transporters
|
CA2618057A1
(en)
|
2005-08-11 |
2007-02-22 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
AU2006311650B2
(en)
*
|
2005-11-08 |
2012-02-23 |
Vertex Pharmaceuticals Incorporated |
Heterocyclic modulators of ATP-binding cassette transporters
|
US7671221B2
(en)
*
|
2005-12-28 |
2010-03-02 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-Binding Cassette transporters
|
WO2007087066A2
(en)
*
|
2005-12-28 |
2007-08-02 |
Vertex Pharmaceuticals Incorporated |
1-(benzo [d] [1,3] di0x0l-5-yl) -n- (phenyl) cyclopropane- carboxamide derivatives and related compounds as modulators of atp-binding cassette transporters for the treatment of cystic fibrosis
|
DK3219705T3
(da)
|
2005-12-28 |
2020-04-14 |
Vertex Pharma |
Farmaceutiske sammensætninger af den amorfe form af n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinolin-3-carboxamid
|
US7645789B2
(en)
|
2006-04-07 |
2010-01-12 |
Vertex Pharmaceuticals Incorporated |
Indole derivatives as CFTR modulators
|
SI2007756T1
(sl)
|
2006-04-07 |
2015-11-30 |
Vertex Pharmaceuticals Incorporated |
Modulatorji prenašalcev z atp-vezavno kaseto
|
US10022352B2
(en)
|
2006-04-07 |
2018-07-17 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-binding cassette transporters
|
CA2652072A1
(en)
*
|
2006-05-12 |
2007-11-22 |
Vertex Pharmaceuticals Incorporated |
Compositions of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
|
US8563573B2
(en)
|
2007-11-02 |
2013-10-22 |
Vertex Pharmaceuticals Incorporated |
Azaindole derivatives as CFTR modulators
|
EP2789606B1
(en)
|
2007-05-09 |
2017-11-15 |
Vertex Pharmaceuticals Incorporated |
Modulators of CFTR
|
AU2008302598B2
(en)
|
2007-08-24 |
2014-07-17 |
Vertex Pharmaceuticals Incorporated |
Isothiazolopyridinones useful for the treatment of (inter alia) Cystic Fibrosis
|
US8551534B2
(en)
*
|
2007-10-10 |
2013-10-08 |
Parion Sciences, Inc. |
Inhaled hypertonic saline delivered by a heated nasal cannula
|
PT2217572E
(pt)
|
2007-11-16 |
2014-02-17 |
Vertex Pharma |
Moduladores de isoquinolina de transportadores de cassete de ligação a atp
|
US20090176839A1
(en)
*
|
2007-12-07 |
2009-07-09 |
Ali Keshavarz-Shokri |
Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
|
US20100036130A1
(en)
*
|
2007-12-07 |
2010-02-11 |
Vertex Pharmaceuticals Incorporated |
Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
|
RS55559B1
(sr)
|
2007-12-07 |
2017-05-31 |
Vertex Pharma |
Čvrste forme 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il) benzoeve kiseline
|
SI2639222T1
(sl)
*
|
2007-12-07 |
2016-12-30 |
Vertex Pharmaceuticals Incorporated |
Proces za izdelavo cikloalkilkarboksiamido-piridin benzojskih kislin
|
CN106432213A
(zh)
|
2008-02-28 |
2017-02-22 |
沃泰克斯药物股份有限公司 |
作为cftr调节剂的杂芳基衍生物
|
US8227615B2
(en)
|
2008-03-31 |
2012-07-24 |
Vertex Pharmaceutical Incorporated |
Pyridyl derivatives as CFTR modulators
|
US20100256184A1
(en)
*
|
2008-08-13 |
2010-10-07 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical composition and administrations thereof
|
AU2009296271A1
(en)
*
|
2008-09-29 |
2010-04-01 |
Vertex Pharmaceuticals Incorporated |
Dosage units of 3-(6-(1-(2,2-difluorobenzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
|
NZ592685A
(en)
|
2008-10-23 |
2013-04-26 |
Vertex Pharma |
Modulators of cystic fibrosis transmembrane conductance regulator
|
EP3330255B1
(en)
*
|
2009-03-20 |
2020-12-09 |
Vertex Pharmaceuticals Incorporated |
Process for making modulators of cystic fibrosis transmembrane conductance regulator
|
MX2012004792A
(es)
*
|
2009-10-22 |
2013-02-01 |
Vertex Pharma |
Composiciones para el tratamiento de fibrosis quistica y otras enfermedades cronicas.
|
US8802868B2
(en)
|
2010-03-25 |
2014-08-12 |
Vertex Pharmaceuticals Incorporated |
Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
|
DK2555754T3
(en)
|
2010-04-07 |
2016-04-18 |
Vertex Pharma |
Solid forms of 3- (6- (1- (2,2-difluoro-benzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamido) -3-methylpyridin-2-yl) -benzoic acid
|
SI3150198T1
(sl)
|
2010-04-07 |
2021-11-30 |
Vertex Pharmaceuticals Incorporated |
Farmacevtski sestavki 3-(6-(1-(2,2-difluorobenzo(D)(1,3)dioksol-5-il) ciklopropankarboksamido)-3-metilpiridin-2-il)benzojske kisline in dajanje le-teh
|
CN103038214B
(zh)
|
2010-04-22 |
2015-09-30 |
弗特克斯药品有限公司 |
制备环烷基甲酰胺基-吲哚化合物的方法
|
AU2011242452A1
(en)
|
2010-04-22 |
2012-11-08 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions and administrations thereof
|
WO2011133953A1
(en)
|
2010-04-22 |
2011-10-27 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions and administrations thereof
|
AU2011255237A1
(en)
*
|
2010-05-20 |
2012-11-29 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions and administrations thereof
|
US8563593B2
(en)
|
2010-06-08 |
2013-10-22 |
Vertex Pharmaceuticals Incorporated |
Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
|
LT2709986T
(lt)
|
2011-05-18 |
2017-05-25 |
Concert Pharmaceuticals Inc. |
Ivakaftoro deuterinti dariniai
|
HUE047354T2
(hu)
|
2011-05-18 |
2020-04-28 |
Vertex Pharmaceuticals Europe Ltd |
Ivacaftor deuterizált származékai
|
US8778383B2
(en)
|
2011-06-07 |
2014-07-15 |
Parion Sciences, Inc. |
Methods of treatment
|
US8945605B2
(en)
|
2011-06-07 |
2015-02-03 |
Parion Sciences, Inc. |
Aerosol delivery systems, compositions and methods
|
AR086745A1
(es)
|
2011-06-27 |
2014-01-22 |
Parion Sciences Inc |
3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
|
CA2852991C
(en)
|
2011-11-08 |
2019-12-31 |
Vertex Pharmaceuticals Incorporated |
Modulators of atp-binding cassette transporters
|
CN109966264A
(zh)
|
2012-02-27 |
2019-07-05 |
沃泰克斯药物股份有限公司 |
药物组合物及其施用
|
US8674108B2
(en)
|
2012-04-20 |
2014-03-18 |
Vertex Pharmaceuticals Incorporated |
Solid forms of N-[2,4-bis(1,1-dimethylethy)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
|
SG11201407867VA
(en)
|
2012-05-29 |
2014-12-30 |
Parion Sciences Inc |
Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye and other mucosal diseases
|
WO2014014841A1
(en)
|
2012-07-16 |
2014-01-23 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions of (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof
|
MY178621A
(en)
|
2012-11-19 |
2020-10-19 |
Vertex Pharmaceuticals Europe Ltd |
Deuterated cftr potentiators
|
CN108484513A
(zh)
|
2012-12-17 |
2018-09-04 |
帕里昂科学公司 |
可用于治疗由黏膜水化不足造成的疾病的氯-吡嗪甲酰胺衍生物
|
ES2674665T3
(es)
|
2012-12-17 |
2018-07-03 |
Parion Sciences, Inc. |
Compuestos de 3,5-diamino-6-cloro-N-(N-(4-fenilbutilo)carbamimidoilo)-pirazina-2-carboxamida
|
RU2671976C2
(ru)
|
2012-12-17 |
2018-11-08 |
Пэрион Сайенсиз, Инк. |
Соединения 3,5-диамино-6-хлор-n-(n-(4-фенилбутил)карбамимидоил)пиразин-2-карбоксамида
|
BR112015023328A2
(pt)
|
2013-03-13 |
2017-07-18 |
Flatley Discovery Lab |
compostos de piridazinona e métodos para o tratamento de fibrose cística
|
DK3068392T5
(da)
|
2013-11-12 |
2021-09-20 |
Vertex Pharma |
Fremgangsmåde til fremstilling af farmaceutiske sammensætninger til behandlingen af cftr-medierede sygdomme
|
US9102633B2
(en)
|
2013-12-13 |
2015-08-11 |
Parion Sciences, Inc. |
Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds
|
CN103787968B
(zh)
*
|
2014-02-27 |
2016-04-13 |
上海湖发化学技术有限公司 |
化合物的制备方法
|
EP3925607B1
(en)
|
2014-04-15 |
2023-06-28 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
|
GB201415381D0
(en)
|
2014-08-29 |
2014-10-15 |
Algipharma As |
Inhalable powder formulations of alginate oligomers
|
EP4159717A1
(en)
|
2014-10-06 |
2023-04-05 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
RU2749213C2
(ru)
*
|
2014-10-07 |
2021-06-07 |
Вертекс Фармасьютикалз Инкорпорейтед |
Сокристаллы модуляторов регулятора трансмембранной проводимости при кистозном фиброзе
|
BR112017010406B1
(pt)
|
2014-11-18 |
2021-03-09 |
Vertex Pharmaceuticals Incorporated |
processo de realização de teste de alta produtividade de cromatografia líquida de alta eficiência
|
GB201504878D0
(en)
|
2015-03-23 |
2015-05-06 |
Algipharma As |
Use of alginate oligomers and CFTR modulators in the treatment of conditions associated with CFTR dysfuntion
|
AU2016327603B2
(en)
|
2015-09-25 |
2021-04-22 |
Vertex Pharmaceuticals (Europe) Limited |
Deuterated CFTR potentiators
|
GB201517639D0
(en)
|
2015-10-06 |
2015-11-18 |
Algipharma As |
Use of alginate oligomers to treat or prevent microbial overgrowth in the intestinal tract
|
CN106187887B
(zh)
*
|
2016-07-01 |
2018-08-14 |
上海工程技术大学 |
4-羟基喹啉-3-甲酸的制备方法
|
WO2018064632A1
(en)
|
2016-09-30 |
2018-04-05 |
Vertex Pharmaceuticals Incorporated |
Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
|
EA202192783A1
(ru)
|
2016-12-09 |
2022-02-24 |
Вертекс Фармасьютикалз Инкорпорейтед |
Модулятор регулятора трансмембранной проводимости при муковисцидозе, фармацевтические композиции, способы лечения и способ получения указанного модулятора
|
MA54105A
(fr)
|
2017-06-08 |
2021-09-15 |
Vertex Pharma |
Méthodes de traitement de la fibrose kystique
|
CA3068609A1
(en)
|
2017-07-01 |
2019-01-10 |
Vertex Pharmaceuticals Incorporated |
Compositions and methods for treatment of cystic fibrosis
|
CA3069226A1
(en)
|
2017-07-17 |
2019-01-24 |
Vertex Pharmaceuticals Incorporated |
Methods of treatment for cystic fibrosis
|
CA3069225A1
(en)
|
2017-07-17 |
2019-01-24 |
Vertex Pharmaceuticals Incorporated |
Methods of treatment for cystic fibrosis
|
WO2019028228A1
(en)
|
2017-08-02 |
2019-02-07 |
Vertex Pharmaceuticals Incorporated |
PROCESSES FOR THE PREPARATION OF PYRROLIDINE COMPOUNDS
|
US11407734B2
(en)
|
2017-10-18 |
2022-08-09 |
Jiangsu Hengrui Medicine Co., Ltd. |
Preparation method for tyrosine kinase inhibitor and intermediate thereof
|
AU2018351533B2
(en)
|
2017-10-19 |
2023-02-02 |
Vertex Pharmaceuticals Incorporated |
Crystalline forms and compositions of CFTR modulators
|
WO2019109021A1
(en)
|
2017-12-01 |
2019-06-06 |
Vertex Pharmaceuticals Incorporated |
Processes for making modulators of cystic fibrosis transmembrane conductance regulator
|
WO2019113089A1
(en)
|
2017-12-04 |
2019-06-13 |
Vertex Pharmaceuticals Incorporated |
Compositions for treating cystic fibrosis
|
EP3720849A2
(en)
|
2017-12-08 |
2020-10-14 |
Vertex Pharmaceuticals Incorporated |
Processes for making modulators of cystic fibrosis transmembrane conductance regulator
|
TWI810243B
(zh)
|
2018-02-05 |
2023-08-01 |
美商維泰克斯製藥公司 |
用於治療囊腫纖化症之醫藥組合物
|
GEP20237571B
(en)
|
2018-02-15 |
2023-11-27 |
Vertex Pharma |
Macrocycles as modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions thereof, their use in the treatment of cycstic fibrosis, and process for making them
|
WO2019195739A1
(en)
|
2018-04-05 |
2019-10-10 |
Alexander Russell Abela |
Modulators of cystic fibrosis transmembrane conductance regulator
|
US11414439B2
(en)
|
2018-04-13 |
2022-08-16 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
|
ES2943126T3
(es)
|
2018-11-14 |
2023-06-09 |
Vertex Pharma |
Métodos para el tratamiento de la fibrosis quística
|
TW202102482A
(zh)
|
2019-04-03 |
2021-01-16 |
美商維泰克斯製藥公司 |
囊腫纖維化跨膜傳導調節蛋白調節劑
|
WO2020214921A1
(en)
|
2019-04-17 |
2020-10-22 |
Vertex Pharmaceuticals Incorporated |
Solid forms of modulators of cftr
|
WO2020226889A1
(en)
*
|
2019-05-07 |
2020-11-12 |
Wellstat Therapeutics Corporation |
Formulations of uridine triacetate in triacetin
|
WO2020242935A1
(en)
|
2019-05-29 |
2020-12-03 |
Vertex Pharmaceuticals Incorporated |
Methods of treatment for cystic fibrosis
|
AU2020328028A1
(en)
|
2019-08-14 |
2022-03-17 |
Vertex Pharmaceuticals Incorporated |
Crystalline forms of CFTR modulators
|
KR20220067551A
(ko)
|
2019-08-14 |
2022-05-24 |
버텍스 파마슈티칼스 인코포레이티드 |
낭성 섬유증 막관통 전도도 조절자의 조절제
|
TW202115092A
(zh)
|
2019-08-14 |
2021-04-16 |
美商維泰克斯製藥公司 |
囊腫纖維化跨膜傳導調節蛋白之調節劑
|
TW202120517A
(zh)
|
2019-08-14 |
2021-06-01 |
美商維泰克斯製藥公司 |
製備cftr調節劑之方法
|
WO2022194399A1
(en)
|
2020-07-13 |
2022-09-22 |
Idorsia Pharmaceuticals Ltd |
Macrocycles as cftr modulators
|
CR20230120A
(es)
|
2020-08-07 |
2023-09-01 |
Vertex Pharma |
Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
|
US20230303589A1
(en)
|
2020-08-13 |
2023-09-28 |
Vertex Pharmaceuticals Incorporated |
Crystalline forms of cftr modulators
|
CN116670143A
(zh)
|
2020-10-07 |
2023-08-29 |
弗特克斯药品有限公司 |
囊性纤维化跨膜传导调控因子的调节剂
|
EP4225764A1
(en)
|
2020-10-07 |
2023-08-16 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
WO2022076618A1
(en)
|
2020-10-07 |
2022-04-14 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
EP4225763A1
(en)
|
2020-10-07 |
2023-08-16 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
US20230373939A1
(en)
|
2020-10-07 |
2023-11-23 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
US20230373935A1
(en)
|
2020-10-07 |
2023-11-23 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
EP4225446A1
(en)
|
2020-10-07 |
2023-08-16 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
EP4225750A1
(en)
|
2020-10-07 |
2023-08-16 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
CN116601158A
(zh)
|
2020-10-07 |
2023-08-15 |
弗特克斯药品有限公司 |
囊性纤维化跨膜传导调控因子的调节剂
|
WO2022190126A1
(en)
*
|
2021-03-09 |
2022-09-15 |
Laurus Labs Limited |
Oral film of cftr modulator(s)
|
TW202333699A
(zh)
|
2022-02-03 |
2023-09-01 |
美商維泰克斯製藥公司 |
囊腫纖維化之治療方法
|
WO2023154291A1
(en)
|
2022-02-08 |
2023-08-17 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
WO2023196429A1
(en)
|
2022-04-06 |
2023-10-12 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
WO2023224931A1
(en)
|
2022-05-16 |
2023-11-23 |
Vertex Pharmaceuticals Incorporated |
Methods of treatment for cystic fibrosis
|
EP4335434A1
(en)
|
2022-08-17 |
2024-03-13 |
Sanovel Ilac Sanayi Ve Ticaret A.S. |
Pharmaceutical compositions comprising ivacaftor
|
WO2024056779A1
(en)
|
2022-09-15 |
2024-03-21 |
Idorsia Pharmaceuticals Ltd |
Crystalline form of (3s,7s,10r,13r)-13-benzyl-20-fluoro-7-isobutyl-n-(2-(3-methoxy-1,2,4-oxadiazol-5-yl)ethyl)-6,9-dimethyl-1,5,8,11-tetraoxo-10-(2,2,2-trifluoroethyl)-1,2,3,4,5,6,7,8,9,10,11,12,13,14-tetradecahydro-[1]oxa[4,7,10,14]tetraazacycloheptadecino[16,17-f]quinoline-3-carboxamide
|
WO2024056798A1
(en)
|
2022-09-15 |
2024-03-21 |
Idorsia Pharmaceuticals Ltd |
Macrocyclic cftr modulators
|
WO2024056791A1
(en)
|
2022-09-15 |
2024-03-21 |
Idorsia Pharmaceuticals Ltd |
Combination of macrocyclic cftr modulators with cftr correctors and / or cftr potentiators
|